Lupin Limited announced the successful completion of global Phase 3 trials for its Lucentis (ranibizumab) biosimilar, LUBT010. This trial, involving 600 patients from India, the US, Europe, and Russia, demonstrated therapeutic equivalence in improving visual acuity in wet AMD patients, matching Lucentis® in safety and immunogenicity. Lupin, which markets ranibizumab in India as RaniEyes, plans to seek marketing approval from the US FDA and European Medicines Agency (EMA). Lupin executives, Dr. Cyrus Karkaria and Mr. Nilesh Gupta, highlighted the company’s commitment to developing cost-effective biosimilars and expanding its global ophthalmic market presence.
